Abatacept for Thalassemia in Children
Phase-Based Progress Estimates
Effectiveness
Safety
The Hospital for Sick Children, Toronto, Canada
Thalassemia in Children+1 More
Abatacept - DrugEligibility
< 65
All Sexes
What conditions do you have?
Select
Eligibility
< 65
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.
Eligible Conditions
- Thalassemia in Children
Treatment Effectiveness
Effectiveness Progress
Other trials for Thalassemia in Children
Study Objectives
3 Primary · 1 Secondary · Reporting Duration: Day +100 until Day +365
Day +100 until Day +365
Number of patients who develop Chronic GVHD
Until Day +100
Number of patients who develop Grade II to IV acute GVHD at Day +100
Number of patients who have WBC engraftment by day +100
Until Day +365
Cost effectiveness
Immune reconstitution
Length of stay
Number of patients who will wean Sirolimus at 1 year post transplant
Trial Safety
Safety Progress
Other trials for Thalassemia in Children
Trial Design
1 Treatment Group
PTIS followed by abatacept and sirolimus
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Abatacept · No Placebo Group · Phase 1 & 2
PTIS followed by abatacept and sirolimusExperimental Group · 2 Interventions: Sirolimus, Abatacept · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sirolimus
2013
Completed Phase 4
~2750
Abatacept
2005
Completed Phase 4
~111470
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day +100 until day +365
Trial Background
Ky Chiang, Staff Physician
Principal Investigator
The Hospital for Sick Children
Closest Location: The Hospital for Sick Children · Toronto, Canada
2014First Recorded Clinical Trial
1 TrialsResearching Thalassemia in Children
399 CompletedClinical Trials
Eligibility Criteria
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Patients must have had a complete evaluation of their iron status including measurement of serum ferritin, MRI of the heart and liver (within the preceding 6 months prior to referral).
You have thalassemia genotype.
You have hepatomegaly.
You have a liver iron content of more than 7mg/g dry weight.
You have a history of severe alloimmunization.
You are able to take oral medication and are willing to adhere to the study regimen.
You have a performance status of at least 70% prior to transplantation.\n
You are unable to tolerate iron chelation.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments